BACKGROUND: Hospital readmission is a significant problem for patients with complex chronic illnesses such as liver cirrhosis. PURPOSE: We aimed to describe the range of readmission risk in patients with cirrhosis and the impact of the model for end-stage liver disease (MELD) score. DATA SOURCES: We conducted a systematic review of studies identified in Ovid MEDLINE, PubMed, EMBASE, CINAHL, the Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov from 2000 to May 2017. STUDY SELECTION: We examined studies that reported early readmissions (up to 90 days) in patients with cirrhosis. Studies were excluded if they did not examine the association between readmission and at least 1 variable or intervention. DATA EXTRAC...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/1/hep29628_am.pdfhttps://deepbl...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144317/1/hep29756-sup-0001-suppinfo1.p...
BACKGROUND: Palliative care (PC) has been shown to be beneficial in end stage liver disease (ESLD), ...
BACKGROUND: Hospital readmission rate is receiving increasing regulatory scrutiny. Patients with cir...
BackgroundEarly hospital readmission for patients with cirrhosis continues to challenge the healthca...
Background: Hospital readmission rate is receiving increasing regulatory scrutiny. Patients with cir...
Background & Aims Patients with cirrhosis have high rates of hospital readmission, but prediction m...
Accurate population‐based data are needed on the rate, economic impact, and the long‐ term outcomes ...
Jingyi Dai,1,2,* Jun Zhao,3,* Yingrong Du,1 Edward B McNeil,2 Virasakdi Chongsuvivatwong21Department...
Background & Aims: Patients with decompensated cirrhosis present frequent hospitalisations with ...
BackgroundPatient portals are a common electronic medical record tool that allow for the asynchronou...
Introduction and aim: Hepatic encephalopathy (HE) is a common complication in cirrhotics and is asso...
Introduction and aim: Considered as a healthcare quality indicator, hospital readmissions in decompe...
Objective: People with chronic liver disease, particularly those with decompensated cirrhosis, exper...
Cirrhosis is the 12th leading cause of death in the United States. By 2020, it is expected to affect...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/1/hep29628_am.pdfhttps://deepbl...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144317/1/hep29756-sup-0001-suppinfo1.p...
BACKGROUND: Palliative care (PC) has been shown to be beneficial in end stage liver disease (ESLD), ...
BACKGROUND: Hospital readmission rate is receiving increasing regulatory scrutiny. Patients with cir...
BackgroundEarly hospital readmission for patients with cirrhosis continues to challenge the healthca...
Background: Hospital readmission rate is receiving increasing regulatory scrutiny. Patients with cir...
Background & Aims Patients with cirrhosis have high rates of hospital readmission, but prediction m...
Accurate population‐based data are needed on the rate, economic impact, and the long‐ term outcomes ...
Jingyi Dai,1,2,* Jun Zhao,3,* Yingrong Du,1 Edward B McNeil,2 Virasakdi Chongsuvivatwong21Department...
Background & Aims: Patients with decompensated cirrhosis present frequent hospitalisations with ...
BackgroundPatient portals are a common electronic medical record tool that allow for the asynchronou...
Introduction and aim: Hepatic encephalopathy (HE) is a common complication in cirrhotics and is asso...
Introduction and aim: Considered as a healthcare quality indicator, hospital readmissions in decompe...
Objective: People with chronic liver disease, particularly those with decompensated cirrhosis, exper...
Cirrhosis is the 12th leading cause of death in the United States. By 2020, it is expected to affect...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146442/1/hep29628_am.pdfhttps://deepbl...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144317/1/hep29756-sup-0001-suppinfo1.p...
BACKGROUND: Palliative care (PC) has been shown to be beneficial in end stage liver disease (ESLD), ...